DoD Researchers Collaborate on Universal Antibody Test for COVID-19
UT Austin Spearheads Scalable, ELISA Antibody Test for SARS-CoV-2
USAMRIID Scientists Engineer First Lethal Mouse Model for COVID-19
Health Security Today – 1 April 2020
USAMRIID Gears Up to Fight COVID-19
USAMRIID Resumes Full Operations Following Federal Select Agent Program Reinstatement
USAMRIID: America’s Key Lab for Fighting Infectious Diseases Has Become a Pentagon Backwater
PharmaJet Receives $9.6 Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices
Why is the Defense Department Withholding Funding for USAMRIID and CCDC Chemical Biological Center?
First-Ever Therapeutic Antibody Cocktail for Sudan Virus Shows Promise in Animal Studies
Henry Eigelsbach, Microbiologist Known for Tularemia Research, Dies at 100
CDC Approves Partial Resumption of USAMRIID Select Agent Research
USAMRIID Study Leads to Approval of New Smallpox Vaccine
Cutting Edge Chemical and Biological Defense Science: Hot Topics at CBD S&T 2019
Biosafety Levels in Laboratories – What is the Difference?
DoD Inspector General to Reevaluate Select Agent Facilities, Biosafety Oversight
How Does USAMRIID Shut Down Impact Nation’s Bioterrorism Laboratory Response Network?
Lawmakers Seek Answers on USAMRIID Shutdown, BioDetection 21 Capabilities
Congratulations. You've reached the end of the internet.
Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response
Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2
Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks
Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3
ABSA’s 1st Biosecurity Symposium
© 2021 by Stemar Media Group LLC
Back to Top